WillItSurvive
Medical technology and health companies · subsidiary of Apollo Hospitals Enterprise Limited (AHEL) · India

Apollo 24/7

apollo247.com ↗

Digital arm of Apollo Hospitals: online pharmacy, doctor consults, diagnostics, insurance.

Losing its protection
Assessed 25 July 2026 · Evidence as of 25 July 2026
The structural protection is eroding.
On the recordSince 25 July 2026 · Checkable from November 2026 · Every call on the record Checkpoint: NCLT ruling on the Apollo Healthtech demerger scheme
The call

Apollo 24/7 has hospitals and pharmacies behind it, but trails Tata 1mg in share and profit while its own listing terms are still unsettled.

Apollo 24/7 runs an online health service that connects patients with doctors, sells medicines, and offers insurance, with thousands of doctors and pharmacies plugged into its system. It is hard to copy because it owns real hospitals and doctors and an insurance license all in one place, but it is losing the race to Tata 1mg, which already makes money and has more customers. Meanwhile, ChatGPT and other AI health chatbots can now answer basic health questions for free, and fast delivery apps like Zepto are stealing medicine sales by promising delivery in ten minutes, so Apollo's profits keep shrinking. The company is also splitting into two separate businesses in early 2027, which adds confusion about what it will be worth and whether anyone will still bet on it.

Why
01
AI pressure: ChatGPT Health and Samsung Health Assistant. Both launch mid-2026 as free AI triage tools that could catch simple health questions before users ever open Apollo's app. Could AI do the core job? Unlikely.
02
Bigger players: Tata 1mg. Tata 1mg holds about 31% of India's digital health market and is already profitable, while Apollo sits near 18% and pre-profit. Could a giant copy it? Probably.
03
What protects it. Apollo's own hospitals, 14,500+ doctors, 6,600+ pharmacies, and an insurance license let it bundle care that app-only rivals can't easily match.
What would change this call
Apollo 24/7 reports platform profitability by Q4FY26 or FY27. Shows whether the profitability turnaround thesis is on track or slipping.
Apollo Healthtech's Q1 2027 listing valuation versus the ~$1.7bn Advent price and ~$2.7bn market expectation. Shows whether investors view the demerged entity as gaining or losing value.
Reliance Healthcare (JioHealth plus Netmeds) ships an integrated hospital-adjacent digital health stack with measurable user traction. Would signal a new large-scale competitor eroding Apollo's integration moat.
Key numbers
  • Digital health share: 18% vs Tata 1mg's 31% (2026)
  • FY25 GMV over ₹3,000 crore, 47M+ users (2025-06-26)
  • Headcount down 22% since 2023 (2026-07-25)
Named risks
  • Demerger into Apollo Healthtech, targeted Q1 2027, could produce weak listing valuation versus prior 1.7bn dollar Advent-implied EV. Severity: high
  • Headcount decline of 22.1% from 2023 to December 2025 signals cost pressure that could limit scaling capacity. Severity: medium
  • Platform profitability target for Q4FY26 could slip, delaying the FY27 EBITDA-positive goal. Severity: high
  • Market share gap versus already-profitable Tata 1mg (31% vs 18%) could widen amid quick-commerce and AI-assistant competition. Severity: medium
  • AI health assistants like ChatGPT Health could compress margins on the triage and wellness layer of the platform. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Tata 1mglosing toTata 1mg holds about 31% e-pharmacy share and turned EBITDA-positive by December 2025, versus Apollo's 18% share
PharmEasycontestingPharmEasy held around 15% market share in 2023 amid its own valuation collapse from 5.6bn dollars
Zepto Pharmacygaining onZepto launched 10-minute medicine delivery across four metros starting August 2025, undercutting on speed
Reliance Netmeds and JioHealthcontestingReliance-backed Netmeds competes directly; a potential integrated JioHealth stack is a watched threat as of 2026
ChatGPT Health and Samsung Health Assistantgaining onBoth launched July 2026, pressuring low-acuity triage and wellness chat layer of digital health platforms
Questions people ask
Is Apollo 24/7 profitable in 2026?
Apollo 24/7 targets platform profitability by Q4FY26 and FY27 EBITDA-positive status, per management guidance from June 2025. The broader Apollo HealthCo segment (including offline pharmacy) posted three straight profitable quarters starting Q2FY25, but the standalone digital platform was not yet confirmed profitable as of mid-2025.
Who owns Apollo 24/7?
Apollo 24/7 sits inside Apollo HealthCo Limited, a subsidiary of listed parent Apollo Hospitals Enterprise Limited (NSE: APOLLOHOSP), founded 1983 by Dr. Prathap C. Reddy. Advent International holds a 12.1% stake after investing 2,475 crore rupees in April 2024. A demerger into separately listed Apollo Healthtech is targeted for Q1 2027.
Could AI replace Apollo 24/7's services?
Generic AI health assistants like ChatGPT Health and Samsung Health Assistant, both launched July 2026, threaten Apollo 24/7's low-acuity triage and wellness chat layer. But prescriptions, licensed consultations, and pharmacy fulfillment remain regulatorily walled off, protected by Apollo's 14,500+ doctors and 6,600+ owned pharmacies as of mid-2026.
Who is Apollo 24/7's biggest competitor?
Tata 1mg leads India's digital health market with roughly 31% share by GMV (2023 data) and reported EBITDA-positive core operations by December 2025, compared to Apollo 24/7's roughly 18% share. Quick-commerce entrant Zepto Pharmacy, launched August 2025, also intensifies price and speed competition in e-pharmacy delivery.
Is joining Apollo 24/7 risky right now for employees?
Apollo HealthCo headcount fell 22.1% from 2,302 employees in 2023 to about 1,794 by December 2025, per Revelio Labs estimates, alongside sharply reduced hiring postings in 2025. The company is also mid-demerger into Apollo Healthtech, targeted for Q1 2027 listing, adding organizational uncertainty.
Is Apollo 24/7 going to list separately from Apollo Hospitals?
Yes. AHEL's board approved a demerger of Apollo HealthCo and Keimed into a new entity, Apollo Healthtech, in June 2025, cleared by India's Competition Commission in September 2025. NCLT approval is targeted for November 2026 with listing expected around Q1 2027; shareholders get 195.2 new shares per 100 AHEL shares.
Timeline
  • 2026-06NCLT shareholder and creditor meetings held for Apollo HealthCo demerger
  • 2025-09-23CCI approves Apollo Hospitals group restructuring into Apollo Healthtech
  • 2025-08-25Apollo 24/7 gains corporate insurance agent approval, 12 insurers, 80 crore rupee year one target
  • 2025-08Zepto Pharmacy launches 10-minute medicine delivery in four Indian metros
  • 2025-07-01AHEL board approves demerger plan to list Apollo HealthCo and Keimed as Apollo Healthtech
  • 2025-06-26Management targets Apollo HealthCo reaching 30,000 crore rupees revenue in 5 to 6 years
  • 2024-04-26Advent International invests 2,475 crore rupees for 12.1% stake in Apollo HealthCo
  • 2021Apollo HealthCo formed by merging Apollo Pharmacy with Apollo 24/7
  • 2020-02Apollo 24/7 launches as Chennai based unified virtual care platform
Revision history
25 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
NeuralinkKingmed DiagnosticsMeinian Onehealth
More in Medical technology and health companies →
Sources